FDA-Approved Uses for Yervoy with Chemotherapy
Yervoy (ipilimumab), a CTLA-4 inhibitor, pairs with chemotherapy in specific metastatic cancers. The FDA approves it with carboplatin and pemetrexed for first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations.[1] It's also approved with carboplatin and paclitaxel for first-line unresectable or metastatic melanoma.[1]
How Yervoy Combines with Chemo in NSCLC
In NSCLC, patients get Yervoy at 1 mg/kg every 6 weeks alongside pemetrexed (500 mg/m²) and carboplatin (AUC 5-6), repeating every 3 weeks up to 4 cycles. Maintenance follows with Yervoy plus pemetrexed every 6 weeks until progression or toxicity. Trials like CheckMate 9LA showed this extends overall survival to 15.7 months versus 11.3 months with chemo alone.[2]
Role in Melanoma Treatment
For melanoma, Yervoy (1 mg/kg every 6 weeks) joins paclitaxel (175 mg/m²) and carboplatin (AUC 6) every 3 weeks for up to 4 cycles, then Yervoy maintenance every 6 weeks. CheckMate 451 data supports this post-anti-PD-1 progression, improving survival in PD-L1-positive cases.[2]
Ongoing Trials and Off-Label Potential
Phase 3 trials test Yervoy plus chemo in triple-negative breast cancer (e.g., CheckMate 7FL), small cell lung cancer, and urothelial carcinoma. Early data hints at benefits in high-tumor-mutation-burden tumors, but approvals await confirmatory results.[3] Off-label use occurs in refractory settings, guided by tumor board review.
Patient Selection Factors
Doctors choose this combo for PD-L1-low NSCLC or BRAF-wildtype melanoma where immunotherapy alone falls short. Avoid in autoimmune disease or prior severe immune reactions due to heightened toxicity risks.[1]
[1]: Yervoy Prescribing Information (FDA)
[2]: CheckMate Trial Publications (NEJM)
[3]: ClinicalTrials.gov Search for Ipilimumab + Chemotherapy